Biopharma Unicorn Moderna Highlights Secretive Pipeline As Investors Await IPO

Moderna is in no rush to conduct an IPO, but the secretive biopharma unicorn gave potential investors in a future offering a glimpse of its 12 programs in or nearing the clinic at J.P. Morgan’s annual conference.